IP Library Patent Application 17061161
Patent Application
App. No. 17/061,161

Therapeutic and Neuroprotective Peptides

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/061,161
Abstract

Nonnatural peptides and their methods of use in human or non-human animal subject to cause an effect such as: nuroprotection, protecting against or lessening nerve impairment or damage, treating glaucoma, treating age-related macular degeneration or other inherited or acquired retinal degenerations, enhancing retinal tissue repair, enhancing retinal regenerative therapy through activation of innate immune cells or treating inherited or acquired retinal degeneration.

Claims (11)

1 .- 13 . (canceled)

14 . A method for improving visual acuity in a human or animal subject who suffers from non-exudative or dry age related macular degeneration, said method comprising the step of:

administering to the subject an effective amount of a compound which comprises Glycinyl-Arginyl-Glycinyl-Cysteic(Acid)-Threonyl-Proline.

15 . A method according to claim 14 wherein the compound is administered intravitreally.

16 . A method according to claim 15 wherein the compound is administered by intravitreal injection.

17 . A method according to claim 14 wherein the compound consists of Glycinyl-Arginyl-Glycinyl-Cysteic-Threonyl-Proline-COOH.

18 . A method according to claim 14 wherein the compound has the formula:

19 . A method according to claim 14 wherein the compound has the formula:

20 . A method according to claim 14 wherein the compound is administered to a subject who has no evidence of sub-retinal fluid and no history of treatment with an anti-VEGF agent.

21 . A method according to claim 14 wherein a dose of 1 mg of the compound is administered intraviterally.

22 . A method according to claim 14 wherein a solution containing 1.0 mg of the compound per 50 μL is injected intraviterally.